Navigation Links
Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
Date:2/4/2009

           -- Aegis Can Now Be Marketed for Use in European Union --
                 -- Neovasc Also Announces Senior Management
                         Changes and Issues Options --

VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), a new specialty vascular device company, today announced that it has received CE mark approval for Peripatch(TM) Aegis, its biocompatible product designed to reduce complications from endoscopic surgery. This approval enables the company to begin marketing Aegis products for sale in the European Union. Peripatch Aegis is a buttressing material designed to reinforce the staple line and prevent bleeding and leaks during bariatric and thoracic endoscopic surgical procedures. Peripatch Aegis products will be marketed in Europe through Neovasc's network of independent distributors.

"Leakage in endoscopic procedures can result in serious complications for patients, so we specifically designed Peripatch Aegis to enable endoscopic surgeons to reinforce surgical staple lines efficiently and effectively," said Alexei Marko, chief executive officer of Neovasc. "We are pleased to have received regulatory clearance to now make this superior product available to surgeons in Europe."

Separately, Neovasc also announced changes to its senior management team. The company is pleased to announce that Cynthia Roney has been appointed to the expanded role of vice president, sales and marketing, adding the responsibilities of the former position of vice president, sales to her portfolio. In addition, Neovasc named Fabio De Pasquale as director, regulatory affairs. Mr. De Pasquale brings over 18 years of industry experience to his new role.

In addition, Neovasc announced today that on February 2, 2009 it granted a total of 427,500 options to the directors and 60,000 options to the senior management of the company. Of these options issued, 312,500 have an exercise price of $0.40, expire five years from the grant date and vest over four years according to the following schedule: 20% vest on the grant date and 20% vest on each of the next four anniversaries of the grant date. The remaining 175,000 options are granted at $0.40, expire after five years and vest immediately. The market price at close of February 2, 2009 was $0.40. The grant of these options is in accordance with the existing stock option plan.

About Neovasc Inc.

Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. Neovasc is comprised of the former Medical Ventures, Neovasc Medical Ltd. and B-Balloon Ltd. The company's current products include, Metricath(R) for intravascular measurement and Peripatch(TM) surgical tissue and staple line reinforcement products. Neovasc has a development pipeline of innovative new products, and provides contract medical device development and manufacturing services. For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.


'/>"/>
SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
5. DaVita Receives Civil Complaint
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
8. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
11. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... Walk Away”: a captivating and romantic sequel to the romantic story of a ... creation of published author, Larry R. Sherman, a retired chemistry professor from the University ... well as four novels. , Though the book opens in 1947, when Edward ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... Although Labor ... of July, many communities have begun providing weekend displays, and numerous households celebrate the ... humans, they can be downright terrifying for pets. , Kris Zambo, owner of ...
(Date:8/21/2017)... ... 21, 2017 , ... Los Angeles area medical group Beverly ... year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one year ... Reconstructive Surgery. The candidate will have the opportunity to work with leading ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
Breaking Medicine Technology: